LUNG CANCER—NON-SMALL CELL METASTATIC

e21153 Publication Only

Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung
cancer.

Laura Fernández Madrigal, Victoria Garcı́a Samblás, Marı́a Amor Urbano, Angel Inoriza; Hospital Juan
Ramon Jimenez, Huelva, Spain; Hospital Juan Ramón Jiménez, Huelva, Spain; Oncologı́a Médica
Hospital Juan Ramón Jiménez Huelva, Huelva, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain

Background: 5% of patients with non-small-cell lung cancer (NSCLC) have a translocation of the ALK
(anaplastic lymphoma kinase) gene on chromosome 2. The phase III clinical trial (ALEX study) analyzed
the efficacy and safety in patients with a diagnosis of NSCLC and ALK mutation -positive (ALK+)
randomized to alectinib versus crizotinib. The objective of our study is to describe our results with
alectinib. Methods: Observational and descriptive study of patients with advanced NSCLC and ALK+
treated with alectinib in the period 2019-2022. Sociodemographic and clinical variables, toxicity
profile, objective response rate (ORR), treatment response and progression free survival (PFS) were
extracted and entered into IBM SPSS Statistics 22 for statistical analysis. Results: 7 patients received
treatment. The median age was 46 years. Baseline characteristics: male (57%); non- Asian race
(100%); non-smoker (57%), ECOG 0-1 (100%). All had adenocarcinoma histology. 57% had liver
metastasis and 37% central nervous system metastasis at the time of diagnosis. The most frequent
symptom was dyspnea (43%). Only one patient was previously terated with 2 lines of chemotherapy
and a 3rd line with crizotinib prior to alectinib. Adjuvant chemotherapy was administered in one
patient. The rest of the participants received alectinib as first line. The most frequent toxicities were:
grade 1-2 increased alanine and aspartate aminotransferase (70%); grade 1 anemia (28.6%); grade 1
increased blood bilirubin (28.6%), skin toxicities (71.5%), myalgia (57%), visual disorders (28.6%);
constipation (28.6%) and sinus bradycardia (14.5%). A 28.6% incidence of dose reductions due to
adverse events (AEs) with alectinib. One patient had to discontinue treatment with alectinib due to
grade 4 AEs consisting of toxic pneumonitis.Hospital admission was required. The ORR was 57.2%.
Complete response ocurred in 28.6% of patients. The median response to treatment was 16 months
and the median PFS was 16 months. Conclusions: The sociodemographic characteristics of our patients
were similar to those described in the ALEX trial. However, the AEs were higher in our study. The ORR
was lower in our study, despite obtaining a high percentage of complete responses. We have a reduced
number of patients who have been treated with alectinib to obtain final conclusions efficacy. Research
Sponsor: None.

© 2023 by American Society of Clinical Oncology. Visit meetings.asco.org and search by abstract for disclosure information.
Downloaded from ascopubs.org by 186.170.34.155 on July 11, 2023 from 186.170.034.155
Copyright © 2023 American Society of Clinical Oncology. All rights reserved.